الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydroklorid - diabetes mellitus, typ 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 och 5. 1 för tillgänglig data på olika kombinationer).

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

dsm sinochem pharmaceuticals netherlands b.v. - amoxicillintrihydrat - dispergerbar tablett - 750 mg - amoxicillintrihydrat 861 mg aktiv substans; aspartam hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

univet ltd - vismutsubnitrat, tungt - intramammär suspension - 2,6 g - vismutsubnitrat, tungt 2,6 g aktiv substans - nöt

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

ebb medical ab - amoxicillintrihydrat - dispergerbar tablett - 1 g - amoxicillintrihydrat 1148 mg aktiv substans; mannitol hjälpämne; aspartam hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

2care4 aps - amoxicillintrihydrat - dispergerbar tablett - 1 g - mannitol hjälpämne; amoxicillintrihydrat 1148 mg aktiv substans; aspartam hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - amoxicillintrihydrat - dispergerbar tablett - 1 g - amoxicillintrihydrat 1147,92 mg aktiv substans; aspartam hjälpämne

السويد - السويدية - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - amoxicillintrihydrat - dispergerbar tablett - 750 mg - aspartam hjälpämne; amoxicillintrihydrat 860,94 mg aktiv substans

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

pfizer europe ma eeig - somatrogon - growth and development - hypofysen och hypotalamus hormoner och derivat - indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone.

الاتحاد الأوروبي - السويدية - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - läkemedel som används vid diabetes - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 och 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.